

DAVITA INC.

ISIN: US23918K1088

WKN: 23918K108

Asset Class: **Stock**

Company

2024/06/14 22:00:02



Price

141.16

USD

Difference

-0.70%(-1.00)



Contact Details

DAVITA INC. Tel: +1-720-631-2100
 -- Fax: +
 2000 16th Street Web: <http://www.davita.com>
 80202-7198 Denver E-mail: -

Company Profile

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 3,137,906,000 | | 3,155,292,000 | | 3,167,723,000 | |
| Common stock capital | | 89,000 | | 90,000 | | 97,000 |
| Fixed assets | 14,481,571,000 | | 14,524,459,000 | | 14,703,283,000 | |
| Equity capital of a company | | 2,743,350,000 | | 2,224,800,000 | | 2,370,980,000 |
| Cash and cash equivalents | 464,634,000 | | 338,989,000 | | 554,960,000 | |
| Accrued liabilities | | 0 | | 0 | | 0 |
| Other assets | - | | - | | - | |
| Current liabilities | | 2,642,214,000 | | 2,619,747,000 | | 2,398,533,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 12,233,913,000 | | 12,835,204,000 | | 13,101,493,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 183,074,000 | | 105,233,000 | | 119,158,000 |
| Total assets | 17,619,477,000 | 17,619,477,000 | 17,679,751,000 | 17,679,751,000 | 17,871,006,000 | 17,871,006,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|----------------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 70,000 | 70,000 | 69,000 |
| Equity ratio | 25.15% | 21.14% | 22.31% |
| Debt-equity ratio | 297.68% | 373.07% | 348.29% |

Others

| | 2023 | 2022 | 2021 |
|-------------------------|--------|--------|--------|
| Tax Expense Rate | 18.70% | 20.50% | 20.20% |

DAVITA INC.

ISIN: US23918K1088

WKN: 23918K108

Asset Class: **Stock**

Income statement

| | 2023 | 2022 | 2021 |
|--|----------------|----------------|----------------|
| Turnover | 12,140,147,000 | 11,609,894,000 | 11,618,797,000 |
| Net income | 691,535,000 | 546,948,000 | 978,450,000 |
| EBIT | 1,370,013,674 | 1,224,791,426 | 1,677,319,099 |
| Operating income before taxes | 1,177,094,000 | 966,278,000 | 1,518,494,000 |
| Cash Flow | 2,063,944,000 | 1,568,532,000 | 1,933,820,000 |
| Net interest income | -304,162,000 | -357,964,000 | -295,020,000 |
| Research and development expenses | - | - | - |
| Income taxes | 220,116,000 | 198,087,000 | 306,732,000 |
| Result from investments in subsidiaries, associates and other | - | - | - |
| Revenues per employee | 160,406 | 153,400 | 155,742 |

Board of Directors

Members of Management Board

| | |
|----------------------|--------------------------------|
| Pamela Arway | Chairman of Board of Directors |
| Gregory Moore | Member of Board of Directors |
| Adam Schechter | Member of Board of Directors |
| Barbara Desoer | Member of Board of Directors |
| Charles Berg | Member of Board of Directors |
| Dennis Pullin | Member of Board of Directors |
| Jason Hollar | Member of Board of Directors |
| Phyllis Yale | Member of Board of Directors |
| Wendy Schoppert | Member of Board of Directors |
| Javier J. Rodriguez | Chairman of Managing Board |
| Christopher M. Berry | Member of Executive Committee |
| James O. Hearty | Member of Executive Committee |
| Jeffrey A. Giullian | Member of Executive Committee |
| Joel Ackerman | Member of Executive Committee |
| Kathleen A. Waters | Member of Executive Committee |
| Kenny Gardner | Member of Executive Committee |
| Michael D. Staffieri | Member of Executive Committee |
| Robert Lang | Member of Executive Committee |